TY - JOUR
T1 - Harnessing the immune system for the treatment of non-small-cell lung cancer
AU - Brahmer, Julie R.
PY - 2013/3/10
Y1 - 2013/3/10
N2 - Over the last several years, new therapeutic targets have emerged in immunotherapy, particularly the immune checkpoint pathways. Blocking inhibitory pathways via monoclonal antibodies, such as the anti- cytotoxic T-lymphocyte antigen-4 antibody (ipilimumab), anti-programmed cell death-1 antibody (BMS-936558), and anti-programmed cell death-1 ligand antibody (BMS-936559), has the ability to break down the shield that tumors co-opt for their defense. Vaccines are able to help the immune system develop immune memory that can have long-lasting, tumor-specific effects. Newer vaccines, particularly the tumor cell vaccine, belagenpumatucel-L, and the antigen-specific vaccines, melanoma-associated antigen-A3, liposomal BLP-25, TG4010, and recombinant human epidermal growth factor, are being evaluated in some of the largest trials ever attempted in lung cancer therapy. These therapies alone or in combination may hold the key to making immunotherapy a reality in the treatment of lung cancer.
AB - Over the last several years, new therapeutic targets have emerged in immunotherapy, particularly the immune checkpoint pathways. Blocking inhibitory pathways via monoclonal antibodies, such as the anti- cytotoxic T-lymphocyte antigen-4 antibody (ipilimumab), anti-programmed cell death-1 antibody (BMS-936558), and anti-programmed cell death-1 ligand antibody (BMS-936559), has the ability to break down the shield that tumors co-opt for their defense. Vaccines are able to help the immune system develop immune memory that can have long-lasting, tumor-specific effects. Newer vaccines, particularly the tumor cell vaccine, belagenpumatucel-L, and the antigen-specific vaccines, melanoma-associated antigen-A3, liposomal BLP-25, TG4010, and recombinant human epidermal growth factor, are being evaluated in some of the largest trials ever attempted in lung cancer therapy. These therapies alone or in combination may hold the key to making immunotherapy a reality in the treatment of lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=84875936184&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875936184&partnerID=8YFLogxK
U2 - 10.1200/JCO.2012.45.8703
DO - 10.1200/JCO.2012.45.8703
M3 - Review article
C2 - 23401435
AN - SCOPUS:84875936184
SN - 0732-183X
VL - 31
SP - 1021
EP - 1028
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 8
ER -